|
157 |
What Biopharma Often Overlooks In A Scheduled Shutdown
|
관리자 |
2026-07-08 |
71 |
|
156 |
Achieving Annex 1 Compliance In Sterile Manufacturing, Part 1: Common Compliance Failures
|
관리자 |
2026-07-08 |
74 |
|
155 |
What are the Requirements for Testing for Impurities in the Pharmaceutical Industry?
|
관리자 |
2026-07-08 |
69 |
|
154 |
Why Isolators Do Not Automatically Ensure Annex 1 Compliance
|
관리자 |
2026-06-05 |
307 |
|
153 |
How Are Service Providers Qualified in a GDP Environment?
|
관리자 |
2026-06-05 |
257 |
|
152 |
CAPA and Root Cause Analysis - why FDA keeps calling them out
|
관리자 |
2026-06-05 |
283 |
|
151 |
Which GMP Requirements Apply to Stability Studies in the Pharmaceutical Industry?
|
관리자 |
2026-05-06 |
697 |
|
150 |
FDA's 483 Playbook: What It Means For Pharma Outsourcing — And What It Doesn't Address
|
관리자 |
2026-05-06 |
684 |
|
149 |
All The Ways Global Biopharma Still Grapples With Annex 1
|
관리자 |
2026-05-06 |
443 |
|
148 |
The Capacity Myth—and What Actually Matters
|
관리자 |
2026-02-27 |
1,046 |
